Cytokine networks in patients with schizoprenia and their possible role in its pathophysiology;Zytokinnetzwerke bei patienten mit schizophrenie und ihre bedeutung für die pathophysiologie der erkrankung

Nervenarzt

Volumn 75, Issue 3, 2004, Pages 215-226

  Schuld, A ^a   Hinze Selch, D ^b   Pollmacher T ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Growth factors; Interleukins; Neuroleptic drugs; Tumor necrosis factor

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

BLOOD; BRAIN DEVELOPMENT; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; EPIDEMIOLOGICAL DATA; HUMAN; MEDICAL RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SMOKING; STRESS;

BRAIN; CELL SURVIVAL; CYTOKINES; HUMANS; NEURONS; PSYCHONEUROIMMUNOLOGY; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 1642413342     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-003-1599-x     Document Type: Review

References (139)

1. Akiyama K (1999) Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 37(1):97-106
2. Andreasen NC, Paradiso S, O'Leary DS (1998), Cognitive dysmetria' as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull 24(2):203-218
3. Arolt V, Rothermundt M, Wandinger KP, Kirchner H (2000) Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 5:150-158
4. Arolt V, Weitzsch C, Wilke I, Nolte A, Pinnow M, Rothermundt M, Kirchner H (1997) Production of interferon-gamma in families with multiple occurrence of schizophrenia. Psychiatry Res 66:145-152
5. Baker I, Masserano J, Wyatt RJ (1996) Serum cytokine concentrations in patients with schizophrenia. Schizophr Res 20(1-2):199-203
6. Barak V, Barak Y, Levine J, Nisman B, Roisman I (1995) Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6(1):61-69
7. Bessler H, Levental Z, Karp L, Modai I, Djaldetti M, Weizman A (1995) Cytokine production in drug-free and neuroleptic-treated schizophrenic patients. Biol Psychiatry 38:297-302
8. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M (2001) Association between G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry 6(1):79-82
9. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH (2001) Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 58(11):1032-1037
10. Burrell R (1994) Human responses to bacterial endotoxin. Circ Shock 43(3):137-153
11. Cazzullo CL, Sacchetti E, Galluzzo A et al.(2002) Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 26(1):33-39
12. Cazzullo CL, Sacchetti E, Galluzzo A, Panariello A, Colombo F, Zagliani A, Clerici M (2001) Cytokine profiles in drug-naive schizophrenic patients. Schizophr Res 47:293-298
13. Cazzullo CL, Scarone S, Grassi B, Vismara C, Trabattoni D, Clerici M. (1998) Cytokine production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 22:947-957
14. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT (2001) Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 50(4):260-265
15. Chiavetto LB, Boin F, Zanardini R et al. (2002) Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biol Psychiatry 51(6):480-484
16. Dantzer R (2001) Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 15(1):7-24
17. Dawson E, Powell JF, Sham PC et al. (199S) An association study of a neurotrophin-3 (NT-3) gene polymorphism with schizophrenia. Acta Psychiatr Scand 92(6):425-428
18. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM (1995) Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 152(3):453-455
19. Dinarello CA (1994) The interleukin-1 family: 10 years of discovery. FASEB J 8:1314-1325
20. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, Thome J (2001) Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52(1-2):79-86
21. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257-269
22. el-Mallakh RS, Suddath RL, Wyatt RJ (1993) Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 17(3):383-391
23. Erbagci AB, Herken H, Koyluoglu O, Yilmaz N, Tarakcioglu M (2001) Serum IL-1β, sIL-2R, IL-6, IL-8 and TNF-α in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment. Mediators Inflamm 10(3):109-115
24. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M (1997) Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 247(4):228-233
25. Ganguli R, Brar JS, Chengappa KR, DeLeo M, Yang ZW, Shurin G, Rabin BS (199S) Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch Gen Psychiatry 52:668-672
26. Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar VL, Rabin BS (1993) Autoimmunity in schizophrenia: a review of recent findings. Ann Med 25(5):489-496
27. Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS (1992) Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 44:113-123
28. Ganguli R, Rabin BS (1989) Increased serum interleukin 2 receptor concentration in schizophrenic and brain-damaged subjects. Arch Gen Psychiatry 46(3):292
29. Ganguli R, Rabin BS, Belle SH (1989) Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 26(4):427-430
30. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS (1994) Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 51(1):1-10
31. Gattaz WF, Dalgalarrondo P, Schröder HC (1992) Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected. Schizophr Res 6(3):237-241
32. Gaughran F, O'Neill E, Cole M, Collins K, Daly RJ, Shanahan F (1998) Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophr Res 29(3):263-267
33. GelernterJ, Van Dyck C, van Kammen DP et al. (1997) Ciliary neurotrophic factor null allele frequencies in schizophrenia, affective disorders, and Alzheimer's disease. Am J Med Genet 74(5):497-500
34. Gill M, Hawi Z, O'Neill FA, Walsh D, Straub RE, Kendler KS (1996) Neurotrophin-3 gene polymorphisms and schizophrenia: no evidence for linkage or association. Psychiatr Genet 6(4):183-186
35. Haack M, Hinze-Sekh D, Fenzel T, Kraus T, Kühn M, Schuld A, Pollmächer T (1999) Plasma levels of cytokines and soluble cytokine receptors in psychiatric pati0ents upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33(5):407-418
36. Haack M, Kraus T, Schuld A, Dalal M, Koethe D, Pollmächer T (2002) Diurnal variations of interleukin-6-plasma levels during sleep and wakefulness are confounded by particularities of blood drawing. Psychoneuroendocrinology 27:921-931
37. Haack M, Reichenberg A, Kraus T, Schuld A, Yirmiya R, Pollmächer T (2000) Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 12(6):694-698
38. Hattori M, Kunugi H, Akahane A et al. (2002) Novel polymorphisms in the promoter region of the neurotrophin-3 gene and their associations with schizophrenia. Am J Med Genet 114(3):304-309
39. Hattori M, Nanko S (1995) Association of neurotrophin-3 gene variant with severe forms of schizophrenia. Biochem Biophys Res Commun 209(2):513-518
40. Hawi Z, Straub RE, O'Neill A, Kendler KS, Walsh D, Gill M (1998) No linkage or linkage disequilibrium between brain-derived neurotrophic factor (BDNF) dinucleotide repeat polymorphism and schizophrenia in Irish families. Psychiatry Res 81(2):111-116
41. Hinze-Selch D, Pollmächer T (2001) In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav Immun 15(4):282-318
42. Hinze-Selch D, Becker EW, Stein GM, Berg PA, Mullington J, Holsboer F, Pollmächer T (1998) Effects of clozapine in in-vitro Immune Parameters: A longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacol 19:114-122.
43. Hornberg M, Arolt V, Wilke I, Kruse A, Kirchner H (1995) Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia. Schizophr Res 15:237-242
44. Hopkins SJ, Rothwell NJ (1995) Cytokines and the nervous system I: expression and recognition. Trends Neurosci 18(2):83-88
45. Johnson HM, Vassallo T, Torres BA (1985) Interleukin 2-mediated events in gamma-interferon production are calcium dependent at more than one site. J Immunol 2:967-970
46. Jonsson E, Brene S, Zhang XR, Nimgaonkar VL, Tylec A, Schalling M, Sedvall G (1997) Schizophrenia and neurotrophin-3 alleles. Acta Psychiatr Scand 95(5):414-419
47. Jun TY, Pae CU, Chae JH, Bahk WM, Kim KS, Han H (2002) Report on IL-10 gene polymorphism at position -819 for major depression and schizophrenia in Korean population. Psychiatry Clin Neurosci 56(2):177-180
48. Karlsson H, Bachmann S, Schroeder J, McArthur J, Torrey EF, Yolken RH (2001) Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci 98(8):4634-4639
49. Katila H, Appelberg B, Hurme M, Rimón R (1994) Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 12(1):29-34
50. Katila H, Cantell K, Hirvonen S, Rimon R (1989) Production of interferon-alpha and gamma by leukocytes from patients with schizophrenia. Schizophr Res 2:361-365
51. Katila H, Hanninen K, Hurme M (1999) Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 4(2):179-181
52. Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimón R (1994) Plasma and cerebrospinal fluid interleukin-1β and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology 30(1):20-23
53. Kim YK, Kim L, Lee MS (2000) Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 44(3):165-175
54. Kim YK, Lee MS, Suh KY (1998) Decreased interleukin-2 production in korean schizophrenic patients. Biol Psychiatry 43(9):701-704
55. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, Licinio J (2002) The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 7(10):1107-1114
56. Kirch DG (1993) Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal. Schizophr Bull 19(2):355-370
57. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, Sokoloff P (2000) Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 5(5):558-562
58. Kronfol Z, Remick DG (2001) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157(5):683-694
59. Kudoh A, Sakai T, Ishihara H, Matsuki A (2001) Plasma cytokine response to surgical stress in schizophrenic patients. Clin Exp Immunol 125(1):89-93
60. Laurent C, Thibaut F, Ravassard P et al. (1997) Detection of two new polymorphic sites in the human interleukin-1 beta gene: lack of association with schizophrenia in a French population. Psychiatr Genet 7(3):103-105
61. Libikova H, Breier S, Kocisova M, Pogady J, Stunzner D, Ujhazyova D (1979) Assay of interferon and viral antibodies in the cerebrospinal fluid in clinical neurology and psychiatry. Acta Biol Med Ger 38(5-6):879-893
62. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients: Am J Psychiatry 150(9):1408-1410
63. Lieberman JA (1999) Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 46(6):729-739
64. Lin A, Kenis G, Bignotti S et al. (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32(1):9-15
65. Mackensen A, Galanos C, Wehr U, Engelhardt R (1992) Endotoxin tolerance: regulation of cytokine production and cellular changes in response to endotoxin application in cancer patients. Eur Cytokine Netw 3(6):571-579
66. Maes M, Bocchio CL, Bignotti S et al. (2000) Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10(2):119-124
67. Maes M, Bocchio Chiavetto L et al.(2002) Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54(3):281-291
68. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29(2):141-152
69. Maes M, Bosmans E, Kenis G, De Jong R, Smith RS, Meltzer HY (1997) In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26(2-3):221-225
70. Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89(5):346-351
71. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R (1995) Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34(4):301-309
72. Maes M, Meltzer HY, Buckley P, Bosmans E (1995) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244(6):325-329
73. Malek-Ahmadi P (1996) Neuropsychiatric aspects of cytokines research: an overview. Neurosci Biobehav Rev 20(3):359-365
74. Meisenzahl EM, Rujescu D, Kirner A, Giegling I, Kathmann N, Leinsinger G, Hahn K, Hegerl U, Möller HJ (2001) Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am J Psychiatry 158(8):1316-1319
75. Mittleman BB, Castellanos FX, Jacobsen LK, Rapoport JL, Swedo SE, Shearer GM (1997) Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 159(6):2994-2999
76. Moises HW, Schindler L, Leroux M, Kirchner H (1985) Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients. Acta Psychiatr Scand 72(1):45-50
77. Monteleone P, Fabrazzo M, Tortorella A, Maj M (1997) Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res 71(1):11-17
78. Muglia P, Vicente AM, Verga M, King N, Macciardi F, Kennedy JL (2003) Association between the BDNF gene and schizophrenia. Mol Psychiatry 8(2):147-148
79. Müller N (1997) The role of the cytokine network in the CNS and psychic disorders. Nervenarzt 68(1):11-20
80. Müller N, Empl M, Riedel M, Schwarz M, Ackenheil M (1997) Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 247(6):308-313
81. Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ (2002) Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 159(6):1029-1034
82. Mullington J, Korth C, Hermann DM, Orth A, Galanos C, Holsboer F, Pollmächer T (2000) Dose-dependent effects of endotoxin on human sleep. Am J Physiol 278(4):R947-R955
83. Naidenova NN, Miriutova TL, Vasil'eva OA (1998) [The interferon system of patients with schizophrenia during therapy]. Zh Nevropatol Psikhiatr Im 5 S Korsakova 88:96-100
84. Nanko S, Hattori M, Kuwata S, Sasaki T, Dai XY, Gill M, Kuwata S, Shibata Y, Kazamatsuri H (1994) Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta Psychiatr Scand 89(6):390-392
85. Naudin J, Mege JL, Azorin JM, Dassa D (1996) Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 20(3):269-273
86. Nimgaonkar VL, Yang ZW, Zhang XR, Brar JS, Chakravarti A, Ganguli R (1995) Association study of schizophrenia and the IL-2 receptor beta chain gene. Am J Med Genet 60(5):448-451
87. Nimgaonkar VL, Zhang XR, Brar JS, DeLeo M, Ganguli R (1995) Lack of association of schizophrenia with the neurotrophin-3 gene locus. Acta Psychiatr Scand 92(6):464-466
88. O'Donnell MC, Catts SV, Ward PB, Liebert B, Lloyd A, Wakefield D, Mc Conaghy N (1996) Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder. Psychiatry Res 65:171-178
89. Oken RJ, Schulzer M (1999) At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull 25(4):625-638
90. Perez-Polo JR, Dy P, Westlund K, Hall K, Livingston K (1978) Levels of serum nerve growth factor in schizophrenia. Birth Defects Orig Artic Ser 14(5):311-321
91. Pollmächer T, Haack M, Schuld A, Kraus T, Hinze-Selch D (2000) Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 34(6):369-382
92. Pollmächer T, Haack M, Schuld A, Reichenberg A, Yirmiya R (2002) Low levels of circulating inflammatory cytokines - do they affect human brain functions? Brain Behav Immun 16:525-532
93. Pollmächer T, Hinze-Selch D, Mullington J (1996) Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16(5):403-409
94. Pollmächer T, Hinze-Selch D, Mullington J, Fenzel T, Holsboer F (1997) Smoking affects plasma-soluble interleukin-2 receptor levels in patients with schizophrenia. Arch Gen Psychiatry 54(1):89
95. Pollmächer T, Korth C Mullington J, Schreiber W, Sauer J, Vedder H, Galanos C, Holsboer H (1996) Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. Blood 87(3)900-905
96. Pollmächer T, Schreiber W, Gudewill S, Vedder H, Fassbender K, Wiedemann K, Trachsel L, Galanos C, Holsboer H (1993) Influence of endotoxin on nocturnal sleep in humans. Am J Physiol 264(6):R1077-R1083
97. Rapaport MH, Lohr JB (1994) Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 90(5):311-315
98. Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM (1989) Elevated levels of soluble interleukin 2 receptors in schizophrenia. Arch Gen Psychiatry 46(3):291-292
99. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM (1997) CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 25(2):123-129
100. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmächer T (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58(5):445-452
101. Riedel M, Krönig H, Schwarz MJ, Engel RR, Kühn KN, Sikorski C, Sokulla S, Ackenheil M, Möller HJ, Müller N (2002) No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. Eur Arch Psychiatry Clin Neurosci 252(5):232-234
102. Rimon R, Ahokas A, Hintikka L (1985) Serum interferon in schizophrenia. Ann Clin Res 17(4):139-140
103. Rothermundt M, Arolt V, Leadbeater J, Peters M, Rudolf S, Kirchner H (2000) Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 11:3385-3388
104. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H (1996) Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry 40:1294-1297
105. Rothermundt M, Arolt V, Weitzsch C, Eckhoff D, Kirchner H (1998) Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 37:186-193
106. Rothwell NJ, Hopkins SJ (1995) Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci 18(3):130-136
107. Roy A, Pickar D, Ninan P, Hooks J, Paul SM (1985) A search for interferon in the CSF of chronic schizophrenic patients. Am J Psychiatry 142(2):269
108. Russo R, Ciminale M, Ditommaso S, Siliquini R, Zotti C, Ruggenini AM (1994) Hepatitis B vaccination in psychiatric patients. Lancet 343:356
109. Sakai T, Sasaki T, Tatsumi M, Kunugl H, Hattori M, Nanko S (1997) Schizophrenia and the ciliary neurotrophic factor (CNTF) gene: no evidence for association. Psychiatry Res 71(1):7-10
110. Schattner A, Cori Y, Hahn T, Sirota P (1996) No evidence for autoimmunity in schizophrenia. J Autoimmun 9(5):661-666
111. Schuld A, Mullington J, Hermann D, Hinze-Selch D, Fenzel T, Holsboer F, Pollmächer T (1999) Effects of granulocyte colony-stimulating factor on night sleep in humans. Am J Physiol 276:R1149-R1155
112. Schwab SG, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, Trixler M, Groß M, Schulze TG, Rietschel M, Lerer B, Maier W, Wildenauer DB (2003) Association of tumor-necrosis-factor alpha gene -g308A polymorphism with schizophrenia. Schizophr Res (im Druck)
113. Shintani F, Kanba S, Maruo N, Nakaki T, Nibuya M, Suzuki E, Kinoshita N, Yagi G (1991) Serum interleukin-6 in schizophrenic patients. Life Sci 49(9):661-664
114. Sirota P, Fishman P, Elizur A, Djaldetti M (1998) Lymphokine production in schizophrenic patients. Biol Psychiatry 27:118A
115. Smith RS (1992) A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med Hypotheses 39(3):248-257
116. Takahashi M, Shirakawa O, Toyooka K et al. (2000) Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5(3):293-300
117. Tanaka KF, Shintani F, Fujii Y, Yagi G, Asai M (2000) Serum interleukin-18 are elevated in schizophrenia. Psychiatry Res 96(1):75-80
118. Tanaka Y, Ujike H, Fujiwara Y, Takeda T, Takehisa Y, Kodama M, Otsuki S, Kuroda S (1998) Schizophrenic psychoses and the CNTF null mutation. Neuroreport 9(6):981-983
119. Tatsumi M, Sasaki T, Sakai T, Kamijuma K, Fukuda R, Kunugi H, Hattori M, Nanko S (1997) Genes for interleukin-2 receptor beta chain, interleukin-1 beta, and schizophrenia: no evidence for the association or linkage. Am J Med Genet 74(3):338-341
120. Theodoropoulou S, Spanakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, Stefanis CN (2001) Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients. Schizophr Res 47(1):13-25
121. Thome J, Durany N, Palomo A, Foley P, Harsany A, Sedvall B, Riederer P (1997) Variants in neurotrophic factor genes and schizophrenic psychoses: no associations in a Spanish population. Psychiatry Res 71(1):1-5
122. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, Nawa H (2002) Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110(3):249-257
123. Tracey KJ, Cerami A (1994) Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 45:491-503
124. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK (1999) Elevated interleukin-6 in schizophrenia. Psychiatry Res 87(2-3):129-136
125. Vawter MP, Dillon-Carter O, Issa F, Wyatt RJ, Freed WJ (1997) Transforming growth factors beta 1 and beta 2 in the cerebrospinal fluid of chronic schizophrenic patients. Neuropsychopharmacology 16(1):83-87
126. Vilcek J (1998) The Cytokines: An Overview. In: Thomson AW (ed) The Cytokine Handbook. 3rd edn. Academic Press, Pittsburgh, pp 1-21
127. Villemain F, Chatenoud L, Guillibert E, Pelicier Y, Bach JF (1987) Decreased production of interleukin-2 in schizophrenia. Ann NY Acad Sci 496:669-675
128. Villemain F, Chatenoud L, Galinowski A, Homo-Delachn F, Ginestet O, Loo H, Zarifan E, Bach JF (1989) Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 146:609-616
129. Virgos C, Martorell L, Valero J, Figuera L, Cirerra F, Joven J, Lombard A, Vililia E (2001) Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 49(1-2):65-71
130. Wagner J (1887) Über die Einwirkung fieberhafter Erkrankungen auf Psychosen. Aligemeine Zeftschrift für Psychiatrie 27:93-131
131. Wassink TH, Crowe RR, Andreasen NC (2000) Tumor necrosis factor receptor-II: heritability and effect on brain morphology in schizophrenia. Mol Psychiatry 5(6):678-682
132. Wassink TH, Nelson JJ, Crowe RR, Andreasen NC (1999) Heritability of BDNF alleles and their effect on brain morphology in schizophrenia. Am J Med Genet 88(6):724-728
133. Wilke I, Arolt V, Rothermundt M, Weitzsch C, Hornberg M, Kirchner H (1996) Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 246:279-284
134. Yang ZW, Chengappa KN, Shurin G, Brar JS, Rabin BS, Gubbi AV, Ganguli R (1994) An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia. Psychol Med 24:449-455
135. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H, Weidenfeld J, Morag A, Newman ME, Pollmächer T (2000) Illness, cytokines, and depression. Ann N Y Acad Sci 917:478-487.
136. Yolken RH, Bachmann S, Rouslanova I, Lillehoj E, Ford G, Torrey EF, Schroeder J (2001) Antibodies to Toxoplasma gondii in individuals with first-episode schizophrenia. Clin Infect Dis 32(5):842-844
137. Yolken RH, Torrey EF (1995) Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 8(1):131-145
138. Zhang M, Tracey K (1998) Tumor Necrosis Factor In: AW Thomson (ed) The Cytokine Handbook. 3rd edn. Academic Press, Pittsburgh, pp 517-549
139. Zhang XY, Zhou DF, Zhang PY, WU GY, Cao LY, Shen YC (2002) Elevated interleukin-2, interleukin,6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57(2-3):247-258